

August 13-14, 2018
Madrid, Spain

Statement of Problem: Globally in 2010 15.5 million people struggled with an opioid use disorder (OUD). OUD is a chronic, relapsing condition leading to significant morbidity and mortality. Since the advent of buprenorphine/naloxone pharmacotherapy with its US FDA approval in 2002, its use has expanded in the US and abroad. This form of medication-assisted treatment (MAT) has been found to decrease mortality and morbidity. Research on long term outcomes of

August 13-14, 2018
Madrid, Spain

Biography

David Hartman completed his medical training at Temple University School of Medicine in Philadelphia, PA; his psychiatric residency at the University of Pennsylvania. He is certified as an Addiction Psychiatrist and in Addiction Medicine and is a DATA 2000 waived physician, credentialed to prescribe buprenorphine. He has been in psychiatric practice in Roanoke, VA since 1982, currently the section chief of Adult Outpatient Psychiatry with Carilion Clinic and is an Associate Professor with the Virginia Tech Carilion School of Medicine. He has created an office-based opioid treatment program at Carilion Clinic, where he has convened a team of practitioners, counselors, care coordinators, and nurses who provide comprehensive treatment services to OUD patients, along with his general psychiatric practice. Academic responsibilities include training medical students, psychiatry residents, and conducting research and quality improvement studies. His research focus